OAKLAND, Calif.--(BUSINESS WIRE)--Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, announced today that it has delivered more than 500 clinical reports for the 100,000 Genomes Project, and has begun to return clinical reports for the project’s main program. These clinical reports are being delivered to Genomics England, leader of the 100,000 Genomes Project, and to multiple Genomic Medicine Centers in the National Health Service (NHS). One of three genomic interpretation partners selected for the project, Omicia was the first to implement its Opal ClinicalTM software within Genomics England’s secure data center and to deliver clinical reports. These interpretive reports may contain actionable information to enable a better understanding of a patient’s disease and can potentially impact patient treatment.
The 100,000 Genomes Project is a groundbreaking, country sequencing program that focuses on rare diseases and cancer. Samples are being collected from NHS patients with a rare disease and their family members, along with cancer patients. The goal is to apply genomic medicine to improve therapeutic treatments. It is currently the largest genome sequencing project of its kind in the world and through this partnership, Omicia is enabling Genomics England to scale actionable results.
“We are thrilled to be closely partnered with Genomics England on this pre-eminent, country-wide sequencing program,” said Charlene Son Rigby, Vice President of Products and Clinical Strategy for Omicia. “The 100,000 Genomes Project will advance the way genomic information is used to improve patient care, and we are honored to provide the highest quality clinical platform and potentially life-saving insights for program participants.”
“Omicia’s technology and expertise help us to achieve our mission of interpreting genomic data on an industrial scale,” said Dr. Damian Smedley, Director of Genomic Interpretation at Genomics England. “We are very grateful for the team’s fast turnaround times and support, which means that NHS clinicians and patients in the 100,000 Genomes Project can be provided with meaningful clinical information.”
Omicia’s OpalTM Clinical software is built on industry-leading proprietary algorithms that vastly accelerate the process of identifying likely disease-causing genes from NGS data. Opal Clinical effectively identifies rare variants and rare genetic disorders, often delivering meaningful insights in less than an hour. Through its work in the 100,000 Genomes Project, Opal Clinical is managing considerable and complex data sets to firmly position Omicia’s suite of products as the solution to scale country genome projects with precision and speed.
Omicia Booth #306
About Genomics England
Genomics England is a wholly owned company of the Department of Health (U.K.), made possible by the National Institute for Health Research, NHS England, Public Health England and Health Education England. Genomics England was created to spearhead the 100,000 Genomes Project. For more information visit www.genomicsengland.co.uk and follow us on Twitter @genomicsengland.
Omicia delivers analysis, interpretation and reporting on genomic data, providing tools to expedite diagnosis, improve medical outcomes and propel today’s precision medicine movement. Omicia fills the need for rapid prioritization of clinically actionable data that has grown with the increasing use of next-generation sequencing in clinical practice. Omicia’s software is used at more than 800 academic and clinical institutions worldwide. Headquartered in Oakland, California with an office in the U.K., Omicia was founded by renowned scientists and industry veterans who are pioneers in bioinformatics, genomics and diagnostics. For additional information, visit www.omicia.com and follow us on Twitter @omicia.